Ironshore Pharmaceuticals & Development, Inc. has developed a novel oral, once-daily, drug delivery technology. DELEXIS has delayed-release properties that limit the release of the medication overnight and extended-release properties that control the release of the medication throughout the following day.
› Learn More About DELEXIS
Our lead products are targeted at helping ADHD patients and their families by leveraging proprietary technologies to address a significant unmet medical need – inadequate control of symptoms of ADHD during the morning routine.
A majority of surveyed families report ADHD symptoms as ‘severe’ or ‘moderate-to-severe’ during the morning routine – the period immediately upon waking until the patient leaves for work or school. This period is often the busiest and most chaotic for families.
Ironshore has developed a proprietary, oral controlled-release technology for evening dosing of medication with delayed and extended release characteristics that is designed to provide for next-day therapeutic activity beginning in the early morning and lasting throughout the day.
